Clinical development success rates for investigational drugs

被引：1660

作者：

Hay, Michael ^{[1
]}

Thomas, David W. ^{[2
]}

Craighead, John L. ^{[3
]}

Economides, Celia ^{[2
]}

Rosenthal, Jesse ^{[1
]}

机构：

[1] Sagient Res Syst, BioMedTracker, San Diego, CA 92122 USA

[2] BIO, Washington, DC USA

[3] Biotech Strategy & Analyt, Rockville, MD USA

来源：

NATURE BIOTECHNOLOGY | 2014年 / 32卷 / 01期

关键词：

PRODUCTIVITY; TRENDS; SCALE; RISKS; SCOPE;

D O I：

10.1038/nbt.2786

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The most comprehensive survey of clinical success rates across the drug industry to date shows productivity may be even lower than previous estimates.

引用

页码：40 / 51

页数：12

共 20 条

[1]

Abrantes-Metz R.M., 2004, Pharmaceutical Development Phases: A Duration Analysis

[2] A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development [J].

Arora, Ashish ;

Gambardella, Alfonso ;

Magazzini, Laura ;

Pammolli, Fabio .

MANAGEMENT SCIENCE, 2009, 55 (10) :1638-1653

[3] Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research [J].

Cockburn, IM ;

Henderson, RM .

JOURNAL OF HEALTH ECONOMICS, 2001, 20 (06) :1033-1057

[4] Macro trends in pharmaceutical innovation [J].

Cohen, FJ .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (01) :78-84

[5] Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances [J].

Danzon, PM ;

Nicholson, S ;

Pereira, NS .

JOURNAL OF HEALTH ECONOMICS, 2005, 24 (02) :317-339

[6] Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs [J].

DiMasi, J. A. ;

Feldman, L. ;

Seckler, A. ;

Wilson, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :272-277

[7] Risks in new drug development: Approval success rates for investigational drugs [J].

DiMasi, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) :297-307

[8] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185

[9] SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES [J].

DIMASI, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :1-14

[10] The Cost of Biopharmaceutical R&D: Is Biotech Different? [J].

DiMasi, Joseph A. ;

Grabowski, Henry G. .

MANAGERIAL AND DECISION ECONOMICS, 2007, 28 (4-5) :469-479

← 1 2 →